Alloy Company Overview and Business Model

What Is Alloy and How Does It Work?

Alloy is a venture-backed telehealth company that connects perimenopausal and postmenopausal women with licensed prescribers who evaluate them for hormone therapy. The entire workflow is online: patients complete an intake questionnaire, a clinician reviews the submission (usually asynchronously), and approved prescriptions ship directly to the patient's door.

The company positions itself as a solution to the well-documented gap in menopause care. A 2019 survey published in Menopause found that only 6.8% of OB/GYN residency programs offered a dedicated menopause curriculum, and just 1 in 5 residents reported feeling "adequately prepared" to manage menopausal patients 1. That training deficit means millions of women struggle to find knowledgeable in-person providers. Alloy's pitch is straightforward: skip the months-long wait for a specialist and get evaluated online.

The company does not manufacture drugs. It prescribes commercially available, FDA-approved formulations (estradiol patches, oral micronized progesterone, vaginal estrogen) and fulfills them through licensed pharmacy partners. This is a standard D2C telehealth model, similar to what Hims, Ro, and Midi Health use in adjacent categories. The differentiator Alloy claims is specialization. Every consultation is routed to a provider credentialed in menopause medicine.

One point worth examining: Alloy's consultations are predominantly asynchronous. A patient fills out forms, and a provider reviews them without a live video visit in most cases. The North American Menopause Society (NAMS) 2022 position statement on hormone therapy notes that individualized risk-benefit assessment is the clinical standard for HRT initiation 2. Whether an asynchronous intake can meet that standard as reliably as a synchronous consultation is a question each patient should weigh.

Alloy's Business Model: Cash-Pay D2C

Alloy operates entirely outside the insurance system. Patients pay out of pocket for both the consultation and the medication. This is common among telehealth startups and has clear advantages and trade-offs.

The advantage is speed. Insurance prior authorizations for HRT can delay treatment by weeks. A 2021 analysis in the Journal of Managed Care & Specialty Pharmacy found that prior authorization adds a median of 3.4 business days to prescription fulfillment, with 15% of requests taking longer than 10 days 3. Cash-pay sidesteps that friction entirely.

The trade-off is cost. Alloy's monthly medication prices typically range from $30 to $85 per product, depending on the formulation. A woman on combination therapy (estradiol patch plus oral progesterone) might spend $50 to $120 per month before factoring in the consultation fee. By comparison, generic estradiol patches filled through insurance often carry a $10 to $25 copay, and oral micronized progesterone (Prometrium generic) runs $5 to $15 with a GoodRx coupon at retail pharmacies.

For a woman without insurance, without a menopause-trained provider nearby, or facing long specialist wait times, the premium may be justified. For a woman with decent prescription coverage and an accessible clinician, the math favors the traditional route. The 2022 Endocrine Society clinical practice guideline on menopausal hormone therapy emphasizes that treatment decisions should not be driven by access barriers alone but by individualized clinical assessment 4.

Alloy also generates revenue through subscription auto-refills and upsells on ancillary products (supplements, skincare). This recurring-revenue model aligns with venture-capital expectations. The company raised $10 million in Series A funding in 2022. That capital structure means growth metrics matter to Alloy's investors, something patients should understand when evaluating how aggressively the platform markets ongoing subscriptions.

What Does Alloy Prescribe?

Alloy's formulary centers on FDA-approved menopausal hormone therapies. The core medications include transdermal estradiol (patches delivering 0.025 mg to 0.1 mg per day), oral micronized progesterone (100 mg or 200 mg nightly), vaginal estrogen (estradiol cream or tablets), and compounded testosterone cream.

The estradiol-plus-progesterone combination is the most widely studied HRT regimen. The Women's Health Initiative (WHI), the largest randomized trial of postmenopausal hormone therapy (N=16,608 for the estrogen-plus-progestin arm), found that while combined equine estrogen plus medroxyprogesterone acetate carried increased breast cancer and cardiovascular risk, the absolute risk increase was small: 8 additional breast cancers per 10,000 woman-years 5. Alloy prescribes bioidentical estradiol and micronized progesterone, not the conjugated equine estrogens and synthetic progestins used in WHI. The KEEPS trial (N=727) demonstrated that transdermal estradiol with cyclic oral progesterone produced favorable cardiovascular and metabolic profiles over 4 years compared to placebo 6.

The testosterone cream offering is notable. Testosterone for female sexual dysfunction is not FDA-approved in the United States, though the International Society for the Study of Women's Sexual Health (ISSWSH) and a 2019 global consensus position statement in the Journal of Clinical Endocrinology & Metabolism endorse its off-label use for hypoactive sexual desire disorder (HSDD) in postmenopausal women 7. A systematic review and meta-analysis of 36 RCTs (N=8,480) published in The Lancet Diabetes & Endocrinology found that testosterone therapy significantly improved sexual function scores, with a standardized mean difference of 0.58 for satisfying sexual events 8.

Alloy uses compounding pharmacies for testosterone cream. Compounded medications are not FDA-approved and lack the batch-consistency testing that commercial products undergo. The FDA's 2023 safety communication on compounded hormone products warns that compounded drugs "may not meet the same safety, quality, and effectiveness standards" as FDA-approved alternatives 9. Patients should ask Alloy's providers specifically about the compounding pharmacy's 503B outsourcing facility status, which subjects the pharmacy to stricter FDA oversight than traditional 503A compounders.

Is Alloy Legit?

Yes, in the regulatory sense. Alloy's prescribers hold active state medical licenses, and the pharmacy partners are state-licensed. The medications prescribed (estradiol, progesterone, vaginal estrogen) carry decades of clinical trial evidence supporting their use for vasomotor symptoms, genitourinary syndrome of menopause (GSM), and bone density preservation.

The more relevant question is whether Alloy's clinical model is thorough enough. A strong menopause evaluation includes personal and family history of breast cancer, cardiovascular risk factors, VTE history, liver disease screening, and (for some women) baseline mammography and lipid panels. The 2022 NAMS position statement lists these assessments as components of a proper pre-HRT evaluation 2. Dr. Stephanie Faubion, NAMS Medical Director, has stated: "Hormone therapy is not one-size-fits-all; the type, dose, route, and timing must be tailored to each woman's symptoms, health risks, and preferences" 2.

Alloy's intake questionnaire asks about many of these risk factors. But a questionnaire is self-reported. It cannot catch the patient who forgets a family history detail or underestimates her cardiovascular risk. Traditional in-person evaluations allow for follow-up questions, physical exam, and real-time clinical judgment. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on menopausal management recommends that clinicians "conduct a thorough history and physical examination" before initiating HRT 10.

This does not make Alloy illegitimate. It means the format has inherent constraints that patients should recognize. For a generally healthy woman with classic vasomotor symptoms and no complex risk factors, an asynchronous telehealth evaluation may be entirely adequate. For a woman with a history of VTE, BRCA mutation carrier status, or active cardiovascular disease, a more hands-on evaluation is warranted.

Alloy vs. Alternatives

Several companies compete with Alloy in the menopause telehealth space. Midi Health, Evernow, and Gennev all offer similar services with varying clinical models and price points.

Midi Health uses synchronous video visits with menopause-trained clinicians and accepts some insurance plans. This addresses two of Alloy's main limitations (asynchronous-only consults and cash-pay-only pricing). Evernow operates a model similar to Alloy's: online questionnaire, asynchronous review, cash-pay. Gennev pairs telehealth visits with health coaching and accepts select insurance.

The clinical evidence base does not differentiate these platforms because they all prescribe the same FDA-approved medications. The differentiators are access model, price, clinical depth, and provider quality. A 2023 cross-sectional study in JAMA Network Open examining D2C telehealth prescribing found that across platforms, clinical documentation quality varied widely, with 34% of encounters lacking documented contraindication screening 11.

For comparison on cost: Midi Health's consultation runs approximately $250 for the initial visit without insurance (less with accepted plans). Alloy's $49 consultation fee is lower, but per-medication costs may offset that savings depending on the formulary. Winona, another competitor, bundles consultation and medication for $89 to $149 per month. The right choice depends on whether a patient values lower upfront cost (Alloy), insurance acceptance (Midi), or bundled pricing (Winona).

Dr. JoAnn Pinkerton, former NAMS Executive Director, has noted: "Women seeking menopause care online should look for providers who follow NAMS or Endocrine Society guidelines and who will order appropriate baseline labs and imaging when indicated" 2. That advice applies regardless of which platform a patient selects.

Clinical Evidence Supporting the Medications Alloy Prescribes

The drugs themselves are not in question. Transdermal estradiol is the preferred route per the 2022 Endocrine Society guideline because it avoids first-pass hepatic metabolism, carries lower VTE risk than oral estrogen, and provides stable serum levels 4. A nested case-control study in the BMJ (N=80,396 VTE cases) found that transdermal estradiol carried no statistically significant increase in VTE risk (OR 0.96 to 95% CI 0.88 to 1.04), while oral estrogen raised risk approximately twofold 12.

Oral micronized progesterone is preferred over synthetic progestins based on observational data from the E3N French cohort (N=80,377), which found that micronized progesterone combined with estradiol showed no significant increase in breast cancer risk over a mean follow-up of 8.1 years (RR 1.00 to 95% CI 0.83 to 1.22), compared to synthetic progestins which carried a significant increase (RR 1.69 to 95% CI 1.50 to 1.91) 13.

Vaginal estrogen for GSM is supported by a 2006 Cochrane review of 37 trials (N=19,676) concluding that local estrogen preparations were equally effective in relieving GSM symptoms regardless of delivery method, and that systemic absorption was minimal at recommended doses 14. The 2020 ACOG Committee Opinion reaffirmed that low-dose vaginal estrogen is appropriate even in breast cancer survivors, stating that systemic absorption is negligible 15.

These are mainstream, guideline-endorsed therapies. Alloy is not prescribing fringe medications. The clinical debate is about delivery model, not drug selection.

Cost Breakdown and Value Assessment

Transparency on cost matters for a cash-pay platform. Based on publicly listed pricing and patient reports, Alloy's approximate costs break down as follows:

Initial consultation: $49. Follow-up consultations: typically included in the subscription or $49 per visit. Estradiol patch (monthly supply): $45 to $55. Oral progesterone (monthly): $30 to $40. Vaginal estrogen cream (monthly): $35 to $50. Compounded testosterone cream (monthly): $45 to $55.

A woman on a common two-drug regimen (estradiol patch plus oral progesterone) would spend roughly $75 to $95 per month through Alloy. The same regimen at a retail pharmacy using GoodRx coupons would cost approximately $25 to $55 per month, but requires an existing prescription from an outside provider.

The premium Alloy charges covers convenience, provider access, and the platform's operational costs (technology, compliance, shipping). Whether that premium represents good value depends on the patient's insurance status, geographic access to menopause specialists, and willingness to manage her own pharmacy logistics.

A 2022 Kaiser Family Foundation brief reported that the average out-of-pocket spending on prescription drugs for women ages 50 to 64 was $1,267 annually 16. For a woman spending $1,000 to $1,200 per year through Alloy on HRT alone, this represents a significant portion of her total drug budget and warrants comparison shopping.

Risks, Limitations, and What to Watch For

Three specific limitations deserve attention before signing up.

First, lab monitoring. Standard menopause care often includes baseline and periodic labs: lipid panel, hepatic function, and (for testosterone therapy) total and free testosterone levels. The Endocrine Society recommends checking serum testosterone 3 to 6 weeks after initiating therapy and periodically thereafter to keep levels within the premenopausal physiologic range 4. Alloy's model should include clear guidance on which labs to obtain and when. Patients should confirm whether their Alloy provider orders labs or whether they need to arrange this independently.

Second, care continuity. D2C telehealth platforms sometimes route patients to different providers at each interaction. Continuity of care is associated with better chronic disease outcomes. A 2018 systematic review in BMJ Open (22 studies, N > 230,000) found that continuity of physician care was associated with lower all-cause mortality (OR 0.82 to 95% CI 0.73 to 0.91) 17. Patients should ask whether they will see the same provider at follow-ups.

Third, compounding quality. For testosterone cream, confirm that Alloy's compounding pharmacy partner is a 503B outsourcing facility registered with the FDA, which requires current good manufacturing practice (cGMP) standards. Products from traditional 503A pharmacies lack this oversight 9.

Who Should Consider Alloy (and Who Should Not)

Alloy may be a reasonable option for perimenopausal or postmenopausal women who have classic vasomotor symptoms (hot flashes, night sweats), have no complex medical history (no personal breast cancer, active VTE, or uncontrolled cardiovascular disease), live in areas with limited access to menopause specialists, and want the convenience of direct-to-door medication delivery.

Alloy is likely not the best fit for women with BRCA1/2 mutations or personal history of hormone receptor-positive breast cancer, women with active or recent venous thromboembolism, women with unexplained vaginal bleeding who need in-person evaluation, or women who prefer synchronous video consultations with a consistent provider.

The NAMS 2022 position statement identifies these conditions as requiring more nuanced, in-person clinical evaluation before hormone therapy can be considered 2.

For women who fall into the straightforward category, Alloy provides a functional pathway to evidence-based HRT that might otherwise require months of waiting for a specialist appointment. The medications are sound. The remaining question is whether the clinical evaluation behind the prescription meets each individual patient's complexity level.